Glucose homeostasis in acromegaly: Effects of long-acting somatostatin analogues treatment

Clinical Endocrinology

Volumn 59, Issue 4, 2003, Pages 492-499

  Baldelli, Roberto ^a,e   Battista, Claudia ^b   Leonetti, Frida ^a   Ghiggi, Maria Rosaria ^b   Ribaudo, Maria Cristina ^a   Paoloni, Antonella ^a   D'Amico, Eugenio ^a   Ferretti, Elisabetta ^a   Baratta, Roberto ^c   Liuzzi, Antonio ^d   Trischitta, Vincenzo ^b   Tamburrano, Guido ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^c UNIVERSITY OF CATANIA   (Italy)

^d ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^e FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; GLUCOSE; HEMOGLOBIN A1C; INSULIN; OCTREOTIDE; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; ADULT; ARTICLE; BODY MASS; CARBOHYDRATE METABOLISM; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; INSULIN SENSITIVITY; LONG TERM CARE; MALE; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; TREATMENT OUTCOME;

ACROMEGALY; ADULT; AGED; AREA UNDER CURVE; BLOOD GLUCOSE; FEMALE; GLUCOSE; GLUCOSE CLAMP TECHNIQUE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HOMEOSTASIS; HUMAN GROWTH HORMONE; HUMANS; INSULIN; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; OCTREOTIDE; PEPTIDES, CYCLIC; PROSPECTIVE STUDIES; SOMATOSTATIN;

EID: 10744228519     PISSN: 03000664     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2265.2003.01876.x     Document Type: Article

References (48)

1. Alberti, K.G.M.M., Christensen, S.E., Christensen, N.J., Hansen, A.P., Iversen, J., Lundbaek, K., Seyer-Hansen, K. & Orskov, H. (1973) Inhibition of insulin secretion by somatostatin. Lancet, 2, 1299-1301.
2. Al-Maskari, M., Gebbie, J. & Kendall-Taylor, P. (1996) The effect of a new slow-release, long-acting somatostatin analogue, lanreotide, in acromegaly. Clinical Endocrinology, 45, 415-421.
3. Baldelli, R., Colao, A., Razzore, P., Jaffrain-Rea, ML., Marzullo, P., Ciccarelli, E., Ferretti, E., Ferone, D., Gaia, D., Camanni, F., Lombardi, G. & Tamburrano, G. (2000) Two-year follow-up of acromegalic patients treated with slow-release lanreotide (30 mg). Journal of Clinical Endocrinology and Metabolism, 85, 4099-4103.
4. Baldelli, R., Dieguez, C. & Casanueva, F.F. (2001) Acromegaly: from basic research to clinical studies. Polish Journal of Endocrinology, 52, 57-79.
5. Barkan, A.L., Kelch, R.P., Hopwood, N.J. & Beitins, I.Z. (1988) Treatment of acromegaly with the long-acting somatostatin analog SMS 201-995. Journal of Clinical Endocrinology and Metabolism, 66, 16-23.
6. Barnard, L.B., William, G., Grantham, G., Lamberton, P., O'dorisio, T.M. & Jackson, I.M.D. (1986) Treatment of resistant acromegaly with a long-acting somatostatin analogue (SMS 201-995). Annals of Internal Medicine, 105, 856-861.
7. Boehm, B.O. & Lusting, R.H. (2002) Use of somatostatin receptor ligands in obesity and diabetic complications. Best Practice in Clinical Gastroenterology, 16, 493-509.
8. Bratusch-Marrain, P.R., Smith, D. & De Fronzo, R.A. (1982) The effect of growth hormone on glucose metabolism and insulin secretion in man. Journal of Clinical Endocrinology and Metabolism, 55, 973-982.
9. Bruno, J.F., Xu, Y. & Song, J. (1993) Tissue distribution of somatostatin receptor subtype messenger ribonucleic acid in the rat. Endocrinology, 133, 2561-1565.
10. Caron, P., Morange-Ramos, I., Cogne, M. & Jaquet, P. (1997) Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide. Journal of Clinical Endocrinology and Metabolism, 82, 18-22.
11. Cerasi, E. & Luft, R. (1964) Insulin response to glucose loading in acromegaly. Lancet, 2, 765-771.
12. Christensen SE, Hansen AP, Orskov H, & Lundbaek K (1978) Twenty-four-hour somatostatin infusions in normals, juvenile diabetics, and maturity-onset diabetics. Metabolism, 27 (Suppl. 1), 1427-1431.
13. Cohen, R., Chanson, P., Bruckert, E., Timsit, J., Legrand, A., Harris, A.G., Guillausseau, P.J., Warnet, A. & Lubetzki, J. (1992) Effects of octreotide on lipid metabolism in acromegaly. Hormone Metabolism Research, 24, 397-400.
14. Colao, A. & Lombardi, G. (1999) Growth hormone excess and PRL excess. Lancet, 352, 1455-1461.
15. Cozzi, R., Dallabonzana, D., Attanasio, R., Barausse, M. & Oppizzi, G. (1999) A comparison between octreotide-LAR and lanreotide-SR in the chronic treatment of acromegaly. European Journal of Endocrinology, 141, 267-271.
16. DECODE Study Group on behalf of the European Diabetes Endocrinology Group (1999) Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic Criteria. Lancet, 354, 617-621.
17. Goedman, H.G. (1968) Growth hormone and the metabolism of carbohydrate and lipid in adipose tissue. Annals of New York Academy of Science, 148, 419-422.
18. De Fronzo, R.A., Tobin, J.D. & Andres, R. (1979) Glucose clamp technique: a method for quantifying insulin secretion and resistance. American Journal of Phisiology, 237, 214-223.
19. Emmer, M.P., Gorden, P. & Roth, J. (1971) Diabetes in association with other endocrine disorders. Medical Clinics of North America, 55, 1057-1064.
20. Fineberg, S.E., Merinee, T.J., Rabinowitz, D. & Edgar, P.J. (1970) Insulin secretion in acromegaly. Journal of Clinical Endocrinology and Metabolism, 30, 288-292.
21. Flogstad, A.K., Halse, J., Bakke, S., Lancranjan, I., Marbach, P., Bruns, C. & Jervell, J. (1997) Sandostatin LAR in acromegalic patients: long-term treatment. Journal of Clinical Endocrinology and Metabolism, 82, 23-28.
22. Foss, M.C., Saad, J.A., Paccola, G.M., Paula, J.A., Piccinato, C.E. & Moreira, A.C. (1991) Peripheral glucose metabolism in acromegaly. Journal of Clinical Endocrinology and Metabolism, 72, 1048-1053.
23. Giustina, A., Barkan, A., Casanueva, F.F., Cavagnini, F., Frohman, L., Ho, K. et al. (2000). Criteria for cure ofacromegaly: a consensus statement. J. Journal of Clin Endocrinology and Metabolism, 85, 526-529.
24. Hansen, I., Tsalikian, E., Beaufrere, B., Gerich, J., Haymond, M. & Rizza, R. (1986) Insulin resistance in acromegaly: defects in both hepatic and extrahepatic insulin action. American Journal of Physiology, 250, 269-273.
25. Ho, K.Y., Jenkins, A.B., Furler, S.M., Borkman, M. & Chisholm, D. (1992) Impact of octreotide, a long-acting somatostatin analogue, on glucose tolerance and insulin sensitivity in acromegaly. Journal of Clinical Endocrinology and Metabolism, 36, 271-279.
26. Iversen, J. (1974) Inhibition of pancreatic glucagon release by somatostatin in vitro. Scandinavian Journal of Clinical Laboratory Investigations, 33, 125-129.
27. James, R.A., Møller, N., Chatterjee, S., White, M & Kendall-Taylor, P. (1991) Carbohydrate tolerance and serum lipids in acromegaly before and during treatment with high-dose octreotide. Diabetic Medicine, 8, 517-523.
28. Jap, T.S. & Ho, L.T. (1990) Insulin secretion and sensitivity in acromegaly. Clinical and Physiological Biochemistry, 8, 64-69.
29. Johansson, C., Wisen, O., Efendic, S. & Uvnas-Wallenstein, K. (1981) Effects of somatostatin on gastrointestinal propagation and absorption of oral glucose in man. Digestion, 22, 126-137.
30. Koerker, D.J., Ruch, W., Chideckel, E., Palmer, J., Goodner, C.J., Ensinck, J. & Gale, C.C. (1974) Somatostatin: hypothalamic inhibitor of the endocrine pancreas. Science, 184, 482-484.
31. Krejs, G.J. (1984) Effects of somatostatin and atropine infusion on intestinal transit time and fructose absorption in the perfused human jejunum. Diabetes, 33, 548-551.
32. Krejs, G.J., Brown, R. & Raskin, P. (1980) Effect of intravenous somatostatin on jejunal absorption of glucose, amino acids, water and electrolytes. Gastroenterology, 78, 26-31.
33. Lamberts, S.W.J., Zweens, M., Verschoor, L. & del Pozo, E. (1986) A comparison among the growth hormone-lowering effects in acromegaly of the somatostatin analog SMS 201-995, bromocriptine, and the combination of both drugs. Journal of Clinical Endocrinology and Metabolism, 63, 16-19.
34. Lawrence, J.H., Tobias, C.A., Linfodt, J.A., Barnn, J., Lyman, T. & Chang, C.Y., Manougian, E. & Wei, W.C. (1970) Successfull treatment of acromegaly: metabolic and clinical studies in 145 patients. Journal of Clinical Endocrinology and Metabolism, 31, 180-188.
35. Luft, R., Cerasi, E. & Hamberger, C.A. (1967) Studies on the pathogenesis of diabetes in acromegaly. Acta Endocrinologica, 56, 593-598.
36. Melmed, S. (1990) Acromegaly. New England Journal of Medicine, 322, 966-977.
37. Mitra, S.W., Mezey, E., Hunyady, B., Chamberlain, L., Hayes, E., Foor, F., Wang, Y., Schonbrunn, A. & Schaeffer, J.M. (1999) Co-localization of somatostatin receptor SST5 and insulin in rat pancreatic beta-cells. Endocrinology, 140, 3790-3796.
38. Møller, N., Pentrany, G., Cassidy, D., Sheldon, W.F., Johnston, D.G. & Laker, M.L. (1988) Effects of SMS 201-995 (Sandostatin) on mouth-to-caecum transit-time and absorption of fat and carbohydrates in normal man. Clinical Science, 75, 345-350.
39. Patel, Y.C. (1997) Molecular pharmacology of somatostatin receptor subtypes. Journal of Endocrinological Investigations, 20, 348-367.
40. Quabbe, H.J. & Plockinger, U. (1989) Dose-response study and long-term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly. Journal of Clinical Endocrinology and Metabolism, 68, 873-881.
41. Reisine, T. & Bell, G.I. (1995) Molecular biology of somatostatin receptors. Endocrine Review, 16, 427-444.
42. Roelfsema, F. & Frolich, M. (1985) Glucose tolerance and plasma immunoreactive insulin levels in acromegalics before and after selective transsphenoidal surgery. Clinical Endocrinology, 22, 531-537.
43. Ronchi, C., Epaminonda, P., Cappiello, V, Beck-Peccoz, P. & Arosio, M. (2002) Effects of two different somatostatin analogs on glucose tolerance in acromegaly. Journal of Endocrinological Investigations, 25, 502-507.
44. Rosenfeld, R.G., Wilson, D.M., Dollar, L.A., Bennett, A. & Hintz, R.L. (1982) Both human pituitary growth hormone and recombinant DNA-derived human growth hormone cause insulin resistance at a post-receptor site. Journal of Clinical Endocrinology and Metabolism, 54, 1033-1038.
45. Sandler, L.M., Burrin, J.M., Williams, G., Joplin, J.F., Carr, D.H. & Bloom, S.R. (1987) Effective long-term treatment of acromegaly with a long-acting somatostatin analogue (SMS 201-995). Clinical Endocrinology, 26, 85-95.
46. Sonksen, P.H., Greenwood, F.C., Ellis, J.P., Lowy, C., Rutherford, A. & Nabarro, J.D.N. (1967) Changes of carbohydrate tolerance in acromegaly with progress of the disease and in response to treatment. Journal of Clinical Endocrinology and Metabolism, 27, 1418-1430.
47. Turner, H.E., Vadivale, A., Keen, J. & Wass, J.A.D. (1999) A comparison of lanreotide and octreotide LAR for treatment of acromegaly. Clinical Endocrinology, 51, 275-280.
48. Verschoor, L., Lamberts, S.W.J., Uitterlinden, P. & Del Pozo, E. (1986) Glucose tolerance during long-term treatment with a somatostatin analogue. British Medical Journal, 293, 1327-1328.